Ignite Creation Date:
2025-12-24 @ 3:03 PM
Ignite Modification Date:
2026-04-24 @ 7:19 PM
Study NCT ID:
NCT02855359
Status:
TERMINATED
Last Update Posted:
2019-03-11
First Post:
2016-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Sponsor:
Seagen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08
Start Date Type:
None
Primary Completion Date:
2018-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-05-15
Completion Date Type:
ACTUAL
First Submit Date:
2016-07-28
First Submit QC Date:
None
Study First Post Date:
2016-08-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-18
Results First Submit QC Date:
None
Results First Post Date:
2019-01-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-02-11
Last Update Post Date:
2019-03-11
Last Update Post Date Type:
ACTUAL